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The immune system comprises a highly integrated network of multiple tissues and cell types with complicated interactions and effects. It is modu-
lated by the endocrine and nervous systems and there is growing realization of its multifunctionality. The session focusing on immunologic effects
of dioxin and related compounds following prenatal exposure involved a review of the immunotoxic effects that have been reported for polyhalo-
genated aromatic hydrocarbons (PHAHs), a discussion of species differences in responses, and development of the immune system, and data from
two ongoing epidemiological studies comparing the immune status of children exposed to higher-than-average concentrations of PHAHs both
prenatally and lactationally. - Environ Health Perspect 103(Suppl 2):157-160 (1995)
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Introduction
Dr. Kerkvliet reviewed the role of the
immune system in health and disease (1,2).
Immunosuppression may result in an
increased incidence of disease from bacte-
ria, viruses, and parasites as well as an
increase in tumors. Inappropriate activa-
tion of the immune system or loss of nor-
mal suppressor cell control is associated
with allergies, hypersensitivity, and autoim-
munity. The immune system involves a
complex network of cells (macrophages,
lymphocytes, other white blood cells) that
communicate via soluble mediators such as
the interleukins and other cytokines. The
interactions are highly regulated. The
macrophage initiates certain immune
responses by taking up foreign materials
nonspecifically and presenting antigens on
its surface to T cells, which become activat-
ed. Various T-cell subtypes secrete different
cytokines, which are involved in the func-
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tion of other T cells as well as controlling
the activity ofB cells.
Studies in the 1970s demonstrated that
TCDD treatment resulted in dramatic
effects on the thymus (3-5). In fact, at rel-
atively high doses of TCDD in adults,
dioxin treatment resulted in atrophy ofthe
lymphoid tissue. However, the ability of
dioxin to modulate a number of immune
responses has been shown to occur at doses
much lower than those resulting in thymic
atrophy. Nevertheless, prenatal effects on
the thymus and/or T-cell-mediated immu-
nity may be critical. The immunotoxic
effects of TCDD have been shown to be
mediated by binding to the Ah receptor,
based on structure/activity studies and use
of mice genetically different in their
responsiveness to TCDD (6-9). The cellu-
lar targets ofTCDD appear to be multiple,
as suggested by the different assays and end
points that have been assessed. While B
cells are clearly targets of TCDD action,
they appear less sensitive than macrophages
and T cells (10). Approaches to studying
the immunotoxicity of TCDD have
involved in vivo, ex vivo, and in vitro
studies (11-13). The in vitro experiments
are very sensitive to culture conditions, and
dioxin's effects appear dependent upon
unknown serum factors (11).
A decrease in the ability to respond to a
primary antibody challenge, often mea-
sured by responsiveness to sheep red blood
cells (SRBC), is a sensitive and repro-
ducible response to dioxin exposure in both
mice and nonhuman primates (8,13,14).
However, the immunotoxicity ofdioxin in
people is unclear. There have only been a
limited number of investigations involving
different study designs and parameters.
Furthermore, there is an inherent difficulty
in measuring the immune status ofhumans
noninvasively, and for any assay that has
been used there is a broad range of "nor-
mal" within the human population. Some
of the assays that have been successfully
used in animals have not been applied to
humans. Often the cohort exposure is not
validated and the immune status often has
been examined long after exposure. The
outstanding issues involve understanding
the mechanism in animal models and basis
for species specificity and sensitivity (15).
The recent reports of alterations in lym-
phocyte subsets induced by TCDD require
validation, both in animal models and in
humans.
Dr. Smialowicz compared the immuno-
toxic effects of TCDD in rats vs mice.
While thymic involution occurs in both
species, the response to the SRBC is clearly
different (16). The ED50 for immunosup-
pression in the mouse is approximately 0.7
jig/kg. In contrast, no immunosuppression
is observed in the rat; instead, an increase
in response to the antigen is observed at
3 pg/kg. Examination ofT-cell phenotypes
revealed no apparent effect due to TCDD
in the mouse, even when the ability to
respond to the SRBC was completely sup-
pressed. In contrast, in two strains of rats
in which response to the antigen was
enhanced by TCDD, there was a decrease
in the T-suppressor population (CD4-
CD8+), an increase in double negative T
cells (CD4-CD8-), and an increase in
IgM+ B cells. These alterations are consis-
tent with enhanced response to a primary
antigen challenge. Whether there are
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changes in other subsets remains to be
determined. Preliminary work on effects of
in utero exposure have also demonstrated a
reduction in thymic cellularity in the rat,
accompanied by a decrease in CD4-CD8+
and CD4+CD8+ cells.
There are also species differences in the
ability of TCDD to compromise host
defenses. Exposure ofthe mouse to TCDD
prior to infection by the parasite trichinella
leads to a decrease in T-cell proliferation in
response to trichinella antigen (17). This
response is comparable to the immunosup-
pression induced by SRBC. This depres-
sion of T-cell proliferation may serve as a
marker for the delayed expulsion of the
parasite that occurs at higher doses. In con-
trast, in the rat there was a suggestion ofan
enhanced T-cell proliferative response and
no evidence of enhanced parasitemia (18).
Response to viral infection appears also to
demonstrate differences between rats and
mice. Doses as low as 10 ng/kg ofTCDD
1 week prior to challenge with influenza
virus resulted in significantly enhanced
mortality in mice (19). However, few if
any effects were seen on viral-induced pul-
monary NKactivity in mice. In contrast, in
rats, using a nonlethal strain of influenza,
effects on viral-augmented NK were
observed at doses of 3 pg/kg (20). Which
rodent is the best model for humans? The
answer is unclear. However, the similarity
in the mouse and nonhuman primate
response to SRBC suggests that the mouse
may be an appropriate surrogate for the
immunotoxic effects ofTCDD in people.
Dr. Gasiewicz reviewed the develop-
ment of the immune system (21), begin-
ning with the yolk sac as the source ofthe
stem cells that invade the developing
mouse thymus on gestation day 11. The
yolk sac is also the source of the cells that
migrate into the fetal liver and thence to
the bone marrow and spleen. There are
self-renewing progenitor cells only in the
fetus which, ifaltered or eliminated results
in changes in the immune repertoire
throughout life. A series of studies has
demonstrated that prenatal and perinatal
exposure to TCDD affects mainly T-cell
responses; few B cell effects are observed,
and only at high doses (4). A number of
investigators have suggested that the devel-
oping embryo/fetus may be more sensitive
than the adult to immunosuppression
induced by TCDD (22-24). It is impor-
tant to note that the immune system ofthe
newborn rodent is much more immature
than that of the human. Early postnatal
rodent immune system development would
occur prenatally in humans.
The fetal thymus also appears to be
more sensitive than the adult thymus.
Dioxin alters thymic differentiation, caus-
ing changes in the total number ofcells in
each lymphocyte subset (25). There may
be an effect on immature populations of
intrathymic cells due to a defect in differ-
entiation. Alternatively, there may be
changes in migration ofcells from the bone
marrow to the thymus (25-27). Recent
studies have examined markers such as ter-
minal deoxynucleotidyl transferase (TdT)
and recombinase activating gene (RAG)
that are present only in lymphoid stem cell
populations and involved in gene
rearrangements. TdT protein and mRNA
decrease following TCDD exposure both
in the fetal liver and bone marrow, while
no effects are noted in the thymus. This
decrease correlates with thymic atrophy as
does a decrease in RAG mRNA. Studies
have demonstrated that the TCDD-treated
prothymocytes are unable to repopulate the
thymus of irradiated mice. This suggests
that a direct effect ofTCDD on bone mar-
row stem cell populations may contribute
to the elicited thymic atrophy. Future stud-
ies are needed to examine the issue of
dose-response relationships, chronic low-
dose effects, effects on B cells, role of
cytokines, and hormonal involvement.
Furthermore, it is necessary to determine if
or how an effect of TCDD on bone mar-
row stem cell populations may affect other,
more subtle, aspects ofthe immune system
other than thymic size. It is important to
note that while estrogen may also produce
thymic atrophy via effects on prothymo-
cytes, the effects of TCDD cannot be
blocked by estrogen receptor antagonists.
Arctic Quebec is the site of an ambi-
tious series of studies discussed by Dr.
Dewailly (28). Infectious disease (e.g.,
meningitis, measles) incidence, as well as
that of otitis, is 20-fold higher in the first
year of life among the Inuit than in indi-
viduals living in southern Quebec. This
appears to be associated with immune dys-
function as measured by a low immuniza-
tion take rate, and raises issues of altered
host resistance. The Inuits have elevated
levels of PCBs, PCDDS, and PCDFs
(29,30). Current investigations are focused
on immunologic examinations ofthe babies
at 2, 6, and 12 months, and comparison of
breast-fed to nonbreast-fed infants. Is
breast feeding protective against disease? Is
breast feeding, due to the high level oflac-
tational transfer ofPHAHs, associated with
elevated disease incidence? There is a sug-
gestion that babies with acute otitis have
been nursed by mothers with higher levels
ofPHAHs or have nursed longer than non-
affected infants. The T-helper/T-suppres-
sor cell ratio may also decrease with
increased exposure, although it is still with-
in the normal range. A negative correlation
was detected between the decrease in
CD4/CD8 ratio and the total toxic equiva-
lency. Prenatal exposure of rodents to
TCDD also appears to result in a decrease
in the relative population of T-helper ver-
sus T-suppressor cells in the thymus.
Further studies are clearlywarranted in this
population, with emphasis on lymphocyte
subset information and determination of
immunization-take rates. In addition, it
would be helpful to have a control popula-
tion whose mothers have "normal" PHAH
levels to examine whether the immunosup-
pressive effects noted are due to prenatal or
lactational exposure.
Dr. Helge stressed the importance of
conducting parallel studies in animals and
humans. In studies of TCDD-exposed
marmosets, changes in the ratio of
CD4+CDW29+ helper cells to CD8+
CD56+ cytotoxic cells were noted follow-
ing extremely low dose (10 ng/kg) treat-
ment of adults (31). However, at even
lower doses, the helper cells actually
increased (32). The meaning ofthe bipha-
sic nature of this response is not clear. In
vitro treatment of marmoset cells results in
suppression ofthe normal stimulatory effect
ofpokeweed mitogen on B cells (33).
Bottle- and breast-fed human infants
are being examined and compared for lym-
phocyte subsets as well as their response to
stimulation by pokeweed mitogen, PMA,
Con A, and anti-CD3. Lower stimulation
by all of these mitogens was observed in
breast-fed infants. This could be associated
with colostrum, which is known to inhibit
stimulation because the lack of mitogen
responsiveness disappeared by the time the
babies were 5 months old. The T-cell sub-
sets are being examined in cord blood and
in the children to determine whether breast
feeding is associated with changes similar
to those observed in the dioxin-treated
marmosets. This population study would
also benefit from a comparison to babies
whose mothers have lower levels ofPHAHs
than in the group currently under examina-
tion for the effects ofbreast feeding.
It is clear that there is a need to develop
sensitive and feasible methods to examine
immune responses in children exposed to
TCDD prenatally, lactationally, or both.
More effort must also be directed at exam-
ining the immune effects that have been
noted to occur in animals, such as the sup-
pression ofthe primary antibody response.
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Alterations in lymphocyte subsets is clearly
a promising area for future investigation,
with potential for use as biomarkers. One
conclusion that appears clear is that
TCDD and related compounds have the
ability to alter differentiation ofcells in the
immune system, as well as in other systems
of the body. Viewing dioxin as a chemical
that has the ability to disrupt cellular dif-
ferentiation puts into perspective not only
its effects on the immune system but also
its dysregulatory role in development ofthe
nervous and reproductive systems.
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